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In this review, recent findings on the effects of tissue and donor origin, culturing conditions and
preconditioning regimens on the therapeutic effect of mesenchymal stem cells (MSC) in organ
transplantation are discussed and the importance of understanding the characteristics of MSC for
developing efficient therapy is stressed.
Recent findings
MSC research in organ transplantation is currently moving from safety-feasibility studies to efficacy studies
and finding the optimal MSC for therapy is therefore highly relevant. Although sharing basic properties,
there are subtle differences between MSC from different tissue sources that may affect their efficacy.
Furthermore, the use of MSC from diseased organ recipients, donor or third party may affect their
therapeutic effect. The importance of these differences in MSC properties may however be overshadowed
by the impact of culture conditions on MSC. Culture conditions dramatically change the characteristics of
MSC, and this situation can be exploited by exposing MSC to preconditioning treatment to bring about the
desired properties in MSC. As MSC appear to be short-lived after infusion, the specific characteristics of
MSC are mostly relevant for short-term interactions between MSC and host cells, which will subsequently
take over the effects of MSC. The multiple effects of MSC are by no means unique, but the full spectrum of
the effects in combination with their easy isolation and expansion make MSC a suitable cell type for
therapy.
Summary
Tissue source, donor source and culture conditions affect the phenotypical and functional properties of
MSC. The efficacy of MSC therapy will therefore depend on the source and manipulation of MSC.
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Mesenchymal stem cells (MSC) are multipotent cells
capable of differentiating inmesodermal lineages, in
particularosteoblastic, adipogenicandchondrogenic
lineages. They have, furthermore, immunomodula-
tory capacities and can inhibit the proliferation of
activated lymphocytes, provide a survival signal to
resting immune cells and stimulate the induction of
regulatory macrophages and regulatory T cells. MSC
are immunophenotypically characterized by the
expression of a panel of markers, including CD29,
CD44, CD73, CD90, CD105, CD166 and HLA class I,
whereas they lack expression of HLA class II and
co-stimulatory molecules CD80 and CD86. Under
inflammatory conditions, the expression of HLA
class II by MSC is induced and the expression of
HLA class I is strongly increased. The properties ofilliams & Wilkins. Unau
Health | Lippincott Williams & WilkMSC have raised interest in the use of these cells for
regenerative and immunomodulatory therapy and
MSC may advance into a therapeutic option for
transplant patients in years to come.MSC are present
in all tissues, from the bone marrow to connective
tissues and solid organs. Traditionally, MSC used for
research and therapeutic purposes are isolated from
the bone marrow, but other tissue sources may turnthorized reproduction of this article is prohibited.
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CKEY POINTS
 Tissue-specific differences of MSC and in-vitro
preconditioning may modulate the therapeutic effect of
MSC in organ transplantation.
 MSC are short lived after infusion and their effects are
likely to be mediated via host immune cells and
allograft resident MSC.
 The effects of MSC are unlikely to be unique; once the
complex molecular pathways that mediate the effects
are elucidated methods to mimic the effects of MSC
may be explored.
Stem cell transplantationout to be of greater benefit as they harbor higher
numbers of MSC or have better accessibility. The
impact of tissue and donor origin, but also of cell
culture conditions, on the properties of MSC is dis-
cussed in this review.TISSUE SOURCE OF MESENCHYMAL
STEM CELLS
MSC from different sources share many pheno-
typical and functional characteristics. There are,
however, subtle differences in differentiation
capacities and expression of specific cell surface
markers. For instance, bone marrow MSC are
negative for CD34, whereas adipose tissue MSC
are positive for CD34 and CD36 early after isolation
[1]. Even within tissues it is believed there are differ-
ent MSC subsets. By using the cell surface markers
CD146 and CD34, MSC of perivascular and non-
perivascular origin can be identified in the stromal
vascular fraction of digested adipose tissue [2,3]. The
suitability of differentMSC subsets for clinical appli-
cation is only starting to be explored.Bone marrow-derived mesenchymal stem
cells
The bone marrow is the classical source of MSC.
Although bone marrow aspirates contain multiple
cell types, a simple plastic adherence selection pro-
cedure is usually sufficient to obtain pure MSC
cultures. Much of the preclinical work with MSC
has been carried out with bone marrow MSC. In
recent years, the use of bonemarrow-derivedMSC in
clinical transplantation has been demonstrated to
be well tolerated and feasible [4–6]. The relatively
large amount of data and experience is a great
advantage for the use of bone marrow MSC, as
opposed to using MSC from alternative tissue
sources that may have different properties. Never-
theless, bone marrow may not be the ultimateopyright © Lippincott Williams & Wilkins. Unautho
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marrow is low [7], and MSC from the bone marrow
do not proliferate as fast as MSC from other tissue
sources [8]. Furthermore, bone marrow aspirations
are invasive and it is unknown whether multiple
bone marrow aspirations affect the MSC compart-
ment in the bone marrow.Adipose tissue-derived mesenchymal stem
cells
Adipose tissue is an emerging source of MSC. It is
easier accessible and can be collected with less bur-
den than bone marrow. Although bone marrow and
adipose tissue MSC share many properties, there are
differences in gene expression profiles, secretion
of growth factors and entry in senescence [9
&
]. It
is important to realize that there are different types
of adipose tissue and that MSC from these tissues
may have different properties. MSC isolated from
abdominal and breast adipose tissue, for instance,
show differences in fibroblast growth factor and
receptor expression, suggesting a difference in their
angiogenic potential [10]. Similar to bone marrow-
derived MSC, infusion of adipose tissue MSC pro-
tects against ischemia-reperfusion injury of the
kidney in murine models [11] by reducing oxidative
stress and inhibiting the inflammatory response
[12]. Adipose tissue MSC furthermore have compar-
able immunomodulatory capacity to bone marrow
MSC and share the capacity of inducing de novo
regulatory T cells [13]. Infusion of adipose tissue
MSC in man is well tolerated [14], but no clinical
studies in organ transplantation have been carried
out up to date.Mesenchymal stem cells from other tissue
sources
MSC are present and can be isolated from multiple
other tissues, such as the skin, muscle, kidney, den-
tal pulp, spleen and heart. However, many of these
tissues are not useful as a source for MSC for clinical
therapy due to their poor accessibility. The blood
would in this respect be the ideal source of MSC, but
the presence of MSC in the circulation is question-
able. Although animal studies have demonstrated
the presence of MSC in the blood [15,16], in human
this has proven problematic. The only report of
circulating MSC in man comes from a study in
hip fracture patients, in which disruption of the
bone marrow could have been the cause of release
of MSC in the circulation [17]. It has been demon-
strated earlier that organ grafts contain donor MSC,
which remain present and functional for multiple
years after transplantation [18,19]. More recently, itrized reproduction of this article is prohibited.
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MSC in organ transplantation Hoogduijn et al.was shown thatMSC reside in the liver and that liver
MSC are mobilized in the perfusion fluid during the
transplantation procedure [20]. Organ perfusates
may therefore be a useful source of donor-derived
MSC. Alternatively, the fetal membrane has been
indicated as a rich source of functional MSC that are
protective against ischemia-reperfusion-induced
kidney injury [21]. The membrane is usually dis-
carded as a waste product after delivery, and there-
fore obtainable in a noninvasive manner. In a
similar manner, MSC can be obtained from umbil-
ical cord blood [8]. The fetal membrane and cord
blood are no practical sources for obtaining autol-
ogous MSC, but they may become useful as sources
of allogeneic MSC.DONOR SOURCE OF MESENCHYMAL
STEM CELLS
The tissue source of MSC is directional for making
the choice of usingMSC of autologous, donor or 3rd
party origin for therapy. Functionality is another
consideration. The in-vitro immunosuppressive
effect of MSC has been demonstrated to be inde-
pendent of HLA subtype and from this perspective
the use of allogeneic MSC for immunomodulatory
therapy is a therapeutic option. Allogeneic cells
may, however, induce an immune response.
Although MSC are considered to be low immuno-
geneic, they can be recognized by the adaptive
immune system [22]. The use of autologous MSC
avoids recognition of the cells by the adaptive
immune system, but alternatively patient-derived
MSC may show reduced functionality compared
with MSC of healthy individuals. Two studies have
investigated the phenotypical and functional
characteristics of bone marrow-derived and adipose
tissue-derived MSC from end-stage renal disease
patients and both concluded that there were no
differences between patient MSC and MSC from
matched healthy individuals [23
&
,24
&
]. These results
justify the use of autologous MSC in clinical trials.
From a logistic, economic and patient burden point
of view, however, the use of third party MSC has
advantages over the use of autologous cells. A study
by Eggenhofer et al. [25
&&
] demonstrated that third
party multipotent adult progenitor cells can tolerize
rats against allogeneic heart grafts. Furthermore,
heart grafts from tolerized rats could be re-trans-
planted without immune suppression in a secon-
dary host. This finding demonstrates that the use of
third party MSC is feasible, well tolerated and effec-
tive in organ transplantation. A study using a model
of autoimmune thyroiditis confirmed the efficacy of
allogeneic MSC and showed no difference in the
effect of autologous and allogeneic MSC on diseaseCopyright © Lippincott Williams & Wilkins. Unau
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occurrence of humoral responses in the animals
treated with allogeneic MSC. Schu et al. [27
&
] made
similar observations and found furthermore that rat
MSC treated with IFN-g were susceptible for cyto-
toxic lysis by CD8þ T cells. The question whether
MSC of allogeneic origin are as effective in a human
outbred population battered with viral infections as
in infection-free inbred laboratory animals will need
further investigation in coming years. Experience in
the setting of hematopoietic stem cell transplan-
tation, in which third party MSC were successfully
used to treat graft versus host disease without side-
effects [28], suggests that the use of third party MSC
in transplant patients is a realistic possibility.
Finally, in transplantation, there is the option to
use MSC of donor origin. A small clinical trial in
kidney transplant recipients demonstrated that the
use of donor-derived MSC is well tolerated and
feasible and may be effective in allowing tapering
of immunosuppressive drugs [29].IMPORTANCE OF CULTURE AND
PRECONDITIONING
Identifying MSC with the most optimal properties
for clinical application is the subject of a great
number of studies. The relevance of tissue-specific
differences between MSC for immunomodulatory
therapy in organ transplantation may, however, be
limited when using culture-expanded MSC. Stand-
ard culture conditions have a major impact on MSC
phenotype and function. Although freshly isolated
MSC have a diameter of 5–6mm, cultured MSC
typically have a diameter of 25–30mm. The volumes
of cultured and noncultured MSC therefore vary
more than 100-fold. Furthermore, in contrast with
MSC in vivo, the proliferation apparatus of cultured
MSC is highly activated and the expression of MSC
surface markers is increased in culture. The impact
of culture on the expression of chemokine receptors
is unknown. Cultured and noncultured MSC may
therefore be home to different sites and have differ-
ent interplays with the immune system. Both cul-
tured and noncultured adipose tissue-derived MSC
have been demonstrated to be effective in amelio-
rating ischemia reperfusion injury of the kidney
[30]. Furthermore, noncultured adipose tissue
MSC have been successfully tested in models of
acute myocardial infarction [31] and cisplatin-
induced kidney injury [32
&
], but so far the efficacy
of nonmanipulated MSC in transplant models
is unknown.
It is known for some time that themanipulation
of culture conditions can modulate the function of
MSC. In the presence of IFN-g, MSC upregulatethorized reproduction of this article is prohibited.
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CStem cell transplantationindoleamine 2,3-dioxygenase (IDO) and thereby
increase their immunosuppressive potency [33].
Improved immunosuppressive capacity of MSC
can also be induced by the inflammatory condi-
tions found in nephritis kidneys [34] or by using
pharmacological compounds such as S-nitroso-N-
acetylpenicillamine [35]. Avoiding pharmacological
interference, variation of oxygen levels may modu-
late the immunosuppressivecapacityofMSC[36]and
glucose levelshavebeen shownto improve theability
of MSC to repair the infarcted myocardium [37].INTERACTION WITH IMMUNE CELLS AND
TISSUE RESIDENT MESENCHYMAL STEM
CELLS
Ironically, although a lot of effort is put in optimiz-
ing MSC preparations for immunomodulatory
therapy, the evidence for sustained engraftment
of intravenously infusedMSC remains inconclusive.
Some studies demonstrated the distribution of
labeled MSC to various tissue sites, among them
to sites of injury [38–40]. Other studies, however,
suggest that MSC have only a limited life time after
infusion. Within 24h after intravenous infusion of
syngeneicMSC inmice, viableMSC can no longer be
detected at any tissue site, not even in ischemic liver
[41
&
]. A study on autopsy material of graft versus
host disease patients demonstrated a low frequency
of donor MSC DNA in lungs and lymph nodes of a
number of patients, and the detection of donor DNA
was negatively correlated with time from infusion to
sample collection [42
&&
].
The potential rapid disappearance of MSC after
infusion does not exclude their therapeutic effect as
even while MSC may only be briefly present, they
rescue hematopoiesis in lethally irradiated mice
[43]. MSC may be recognized and cleared by the
innate immune system because of their cell culture-
modulated phenotype. The in-vivo effects of MSC
that are observed in several transplantmodels can be
explained by the interaction between MSC and cells
of the immune system and the transfer of immuno-
modulatory effects from MSC to other cell types
before MSC are cleared. Even though MSC may be
short-lived, tissue-specific differences and culture-
induced preconditioning of MSC may become
relevant for the brief interaction between MSC
and other immune cell types, such as macrophages
and regulatory T cells. MSC are known to directly
induce the generation of regulatory T cells and, in
addition, a study in murine demonstrated that sple-
nectomy abolished the therapeutic effect of MSC on
acute kidney injury by inhibiting the formation of
regulatory T cells, suggesting that MSC induce regu-
latory T cells through interactions with splenocytesopyright © Lippincott Williams & Wilkins. Unautho
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regulatory phenotype [45] and macrophages that
phagocytose dead MSC obtain regulatory properties
[46
&
]. This situation indicates that the clearing up
process of MSC in itself is an immunomodulatory
mechanism of MSC therapy. Specific properties of
MSC preparations are likely to affect the response of
macrophages to MSC.
Next to their effect on immune cells, adminis-
tration of MSC may affect tissue resident MSC.
Infusion of MSC leads to a systemic cytokine
response [47] and this response may reach MSC that
are present in tissues, including in organ trans-
plants. For instance, the pancreas is home to MSC
that can be exploited for islet neogenesis [48] and
targeting of these MSC may modulate their regen-
erative and immunomodulatory properties. MSC in
lung allografts are indicated to be involved in
inflammation-induced fibrogenesis [49]. The func-
tion of these MSC may be modulated by MSC
therapy to bring about their immunomodulatory
properties and suppress their fibrotic properties.UNIQUENESS OF THE MESENCHYMAL
STEM CELLS EFFECT
MSC are defined by a number of phenotypical and
functional characteristics. As reviewed above, MSC
exploit these characteristics to bring about their
regenerative and immunomodulatory effects by
directly targeting host cells and by targeting cells
indirectly via cellular intermediates. Subtle differ-
ences between MSC of various tissues and precon-
ditioning regimens will refine the interaction
between MSC and host cells. The full spectrum of
molecules and signaling pathways that mediate the
effects of MSC therapy is currently unknown. It is
unlikely that the mechanisms mediating the effect
of MSC are specific and are not utilized by other cell
types to mediate the same effects. In vitro, for
instance, IDO is important for the immunomodu-
latory effects ofMSC, but fibroblasts can also express
IDO and, like MSC, can inhibit T-cell proliferation
and expand regulatory T cells [50]. Proximal tubular
epithelial cells can inhibit the proliferation of auto-
logous T and B lymphocytes, partly via the pro-
grammed death ligand 1 pathway [51], thereby
mimicking the effect of MSC. There are few direct
comparisons between the in-vivo immunomodula-
tory effects of MSC and other cell types. A study in
an ischemic skin model in the rabbit demonstrated
similar effects of MSC and dermal fibroblasts on
wound healing [52]. Particular aspects of the effect
of MSC therapy may therefore be replaced by other
cells or pharmacological compounds. However,
replacement of the whole spectrum of MSC therapyrized reproduction of this article is prohibited.
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MSC in organ transplantation Hoogduijn et al.will need far more detailed knowledge on the mech-
anisms of MSC treatment. Furthermore, as MSC are
relatively easy to access, isolate and expand, finding
a more efficient cell type will be very challenging.CONCLUSION
Tissue source, donor-origin and culture conditions
have an impact on the properties of MSC and can
affect their interaction with host immune and tissue
resident cells. MSC with different properties may
have different effects on the outcome of organ
transplantation. Future research should be aimed
at dissecting out those properties of MSC that are
instrumental for their therapeutic effect. These
studies can then lead to optimization ofMSC therapy
by generating an MSC product that possesses these
properties.
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